OptiBiotix Health Past Earnings Performance
Past criteria checks 0/6
OptiBiotix Health's earnings have been declining at an average annual rate of -35.4%, while the Biotechs industry saw earnings growing at 7.7% annually. Revenues have been declining at an average rate of 14.1% per year.
Key information
-35.4%
Earnings growth rate
-35.0%
EPS growth rate
| Biotechs Industry Growth | -14.6% |
| Revenue growth rate | -14.1% |
| Return on equity | -40.5% |
| Net Margin | -524.4% |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses Breakdown
How OptiBiotix Health makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 1 | -3 | 2 | 0 |
| 31 Mar 24 | 1 | -3 | 2 | 0 |
| 31 Dec 23 | 1 | -2 | 2 | 0 |
| 30 Sep 23 | 1 | -8 | 2 | 0 |
| 30 Jun 23 | 1 | -13 | 2 | 0 |
| 31 Mar 23 | 1 | -5 | 2 | 0 |
| 31 Dec 22 | 0 | 3 | 3 | 0 |
| 30 Sep 22 | 1 | 4 | 2 | 0 |
| 30 Jun 22 | 1 | 6 | 2 | 0 |
| 31 Mar 22 | 2 | 6 | 2 | 0 |
| 31 Dec 21 | 2 | 6 | 2 | 0 |
| 30 Sep 21 | 2 | 13 | 2 | 0 |
| 30 Jun 21 | 2 | 21 | 2 | 0 |
| 31 Mar 21 | 2 | 13 | 2 | 0 |
| 31 Dec 20 | 2 | 6 | 2 | 0 |
| 31 Dec 19 | 1 | -2 | 2 | 0 |
| 31 May 19 | 1 | -2 | 2 | 0 |
| 28 Feb 19 | 1 | -2 | 2 | 0 |
| 30 Nov 18 | 1 | -2 | 2 | 0 |
| 31 Aug 18 | 0 | -2 | 2 | 0 |
| 31 May 18 | 0 | -2 | 2 | 0 |
| 28 Feb 18 | 0 | 0 | 2 | 0 |
| 30 Nov 17 | 0 | 2 | 2 | 0 |
| 31 Aug 17 | 0 | 2 | 2 | 0 |
| 31 May 17 | 0 | 2 | 1 | 0 |
| 28 Feb 17 | 0 | 1 | 1 | 0 |
| 30 Nov 16 | 0 | -1 | 1 | 0 |
| 31 Aug 16 | 0 | -1 | 1 | 0 |
| 31 May 16 | 0 | -1 | 1 | 0 |
| 29 Feb 16 | 0 | -1 | 1 | 0 |
| 30 Nov 15 | 0 | -1 | 1 | 0 |
| 31 Aug 15 | 0 | -1 | 1 | 0 |
| 31 May 15 | 0 | -1 | 1 | 0 |
| 28 Feb 15 | 0 | -1 | 1 | 0 |
| 30 Nov 14 | 0 | -1 | 0 | 0 |
| 31 May 14 | 0 | 0 | 0 | 0 |
| 28 Feb 14 | 0 | -1 | 0 | 0 |
Quality Earnings: OB3 is currently unprofitable.
Growing Profit Margin: OB3 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: OB3 is unprofitable, and losses have increased over the past 5 years at a rate of 35.4% per year.
Accelerating Growth: Unable to compare OB3's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: OB3 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-18.2%).
Return on Equity
High ROE: OB3 has a negative Return on Equity (-40.52%), as it is currently unprofitable.